Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 196

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 196
---
 member since 2010, and is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. In January 1968, he was appointed as Senior Scientist, Department of Biochemistry, at the Weizmann Institute of Science. In January 1968, he was appointed at the Weizmann Institute of Science, Rehovot, Israel, where he has been a full -timeProfessor since January 1973, heading for several periods the Departments of Virology and of Molecular Genetics. His research on Interferon, its mechanisms of action and the isolation of the human Interferon -betagene, have led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. 86 Eran Iohan, Independent Director Mr.Eran Iohan has served as a director of Kadimastem since October of 2022, Mr.Iohan brings with him over 20 years of financial, accounting, and managerial experience, leading IPOs, follow -oninvestments, and complex transaction in Israel and US for technology and bio -technologycompanies. From December of 2019 until today, Mr.Iohan has been a director of My Green Fields. From January of 2019 until current, Mr.Iohan has served as the Founder of Thin Places. From March of 2021 until June of 2023 he served as Chief